The Latest Breaking News from AbbVie Inc

The bear market is creating a challenging environment for investors. One place to find outperformance could be high0-quality, healthcare stocks that are paying a dividend. Therefore, investors should consider dividend-paying healthcare stocks like Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), and Unitedhealth Group (UNH).   .

AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug Administration to support the preventive treatment of chronic migraine in adults.

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy.  AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease. The trial included patients who had an inadequate response or were intolerant to conventional or biologic therapy.  A significantly higher proportion of patients who received upadacitinib 15 mg or 30…

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) and AbbVie Inc's (NYSE:ABBV) Allergan Plc are willing to pay more than $5 billion combined to resolve more than 3,500 lawsuits filed over highly addictive opioid painkillers, according to three people familiar with settlement talks.  The people said the companies have been in mediation talks with plaintiffs for more than a year. …

Myovant Sciences Ltd (NYSE:MYOV) received European approval for Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer, and SVB Securities think Orgovyx could be a ~$1 billion product in advanced prostate cancer long term. But the surprise Myfembree setback in endometriosis has sparked uncertainty and new investor questions for Myovant's 2nd program. Hence, SVB remains on the…

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

San Francisco will start a trial against Walgreens Boots Alliance Inc (NASDAQ:WBA) and three other companies accused of fueling an opioid crisis in the city. San Francisco has alleged that Walgreens, Teva Pharmaceutical Industries Ltd (NYSE:TEVA), AbbVie Inc's (NYSE:ABBV) Allergan unit, and Teva-owned Anda Inc created a "public nuisance" by flooding the city with prescription opioids and failing…

Alabama reached $276 million in settlements with Johnson & Johnson (NYSE:JNJ), McKesson Corporation (NYSE:MCK), and Endo International Plc (NASDAQ:ENDP), resolving claims on the opioid addiction crisis, the state attorney general said. McKesson will pay $141 million. JNJ and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement.  The three…